Feb 10 (Reuters) – Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating expectations for fourth-quarter results on strong demand for its diagnostic tests.
The laboratory operator expects its 2026 adjusted profit to be in the range of $10.50 to $10.70 per share, compared with estimates of $10.43, according to data compiled by LSEG.
Quest expects annual revenue between $11.7 billion and $11.82 billion, above analysts’ average estimate of $11.39 billion.
Shares of the New Jersey-based company were up 1.4% in premarket trading.
The results and forecast point to improving conditions for diagnostic testing, as demand for non-urgent surgeries, particularly among older Americans, lifts volumes, with Quest and peer Labcorp also leaning on hospital lab management deals to drive market share gains.
The company said in October it expected legislation, including the Trump administration’s One Big Beautiful Bill Act, and the recently expired enhanced Affordable Care Act tax credits, to not have a material impact on revenue in 2025 and 2026.
Quest’s revenue for the fourth quarter rose 7.1% to $2.81 billion, above analysts’ average estimates of $2.75 billion.
On an adjusted basis, the company posted a quarterly profit of $2.42 per share, beating estimates of $2.36.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Maju Samuel)
